Aran Research & Development (1982) (XTAE:ARAN) EBIT: ₪33.6 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:ARAN Aran Research & Development (1982) Ltd XTAE:ARAN
78 GF Score
Price ₪39.78
GF Value ₪37.11
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Aran Research & Development (1982) EBIT?

Aran Research & Development (1982) XTAE:ARAN +1.20% 78 EBIT is ₪33.6 Mil as of Dec. 2025. GuruFocus rates XTAE:ARAN with a GF Score™ of 78/100 and a GF Value™ of ₪37.11 (Fairly Valued). The stock has 2 warning signs investors should review.

Aran Research & Development (1982)'s earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was ₪23.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was ₪33.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Aran Research & Development (1982)'s annualized ROC % for the quarter that ended in Dec. 2025 was 7.94%. Aran Research & Development (1982)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 79.83%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Aran Research & Development (1982)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 20.54%.

Aran Research & Development (1982)  (XTAE:ARAN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Aran Research & Development (1982)'s annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=12.596 * ( 1 - 22.32% )/( (127.627 + 118.945)/ 2 )
=9.7845728/123.286
=7.94 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=193.011 - 47.673 - ( 17.711 - max(0, 61.162 - 144.431+17.711))
=127.627

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=213.252 - 40.548 - ( 53.759 - max(0, 89.226 - 169.195+53.759))
=118.945

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Aran Research & Development (1982)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=46.596/( ( (24.397 + max(47.365, 0)) + (25.158 + max(19.815, 0)) )/ 2 )
=46.596/( ( 71.762 + 44.973 )/ 2 )
=46.596/58.3675
=79.83 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(73.271 + 15.987 + 5.78) - (47.673 + 0 + -7.105427357601E-15)
=47.365

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(66.485 + 14.532 + 16.989) - (40.548 + 0 + 37.643)
=19.815

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Aran Research & Development (1982)'s Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=33.637/163.767
=20.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aran Research & Development (1982) EBIT Related Terms

Aran Research & Development (1982) EBIT Historical Data

* Premium members only.

The historical data trend for Aran Research & Development (1982)'s EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aran Research & Development (1982) EBIT Chart

Aran Research & Development (1982) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.84 41.47 12.52 11.04 33.64

Aran Research & Development (1982) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.43 4.10 6.94 10.34 23.30

XTAE:ARAN vs MMM, HON: EBIT Comparison

For the Conglomerates subindustry, Aran Research & Development (1982)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aran Research & Development (1982) EV-to-EBIT vs Conglomerates Industry

For the Conglomerates industry and Industrials sector, Aran Research & Development (1982)'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Aran Research & Development (1982)'s EV-to-EBIT falls into.


XTAE:ARAN
78GF Score
Aran Research & Development (1982) Ltd XTAE:ARAN
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aran Research & Development (1982) EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₪33.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₪33.6 Mil mean?
Aran Research & Development (1982) (XTAE:ARAN) has a EBIT of ₪33.6 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Aran Research & Development (1982).
Is Aran Research & Development (1982)'s EBIT too high?
Aran Research & Development (1982)'s current EBIT is ₪33.6 Mil. Overall, Aran Research & Development (1982) has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aran Research & Development (1982)'s EBIT compare to MMM and HON?
Aran Research & Development (1982)'s EBIT of ₪33.6 Mil can be compared against companies in the Conglomerates industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Conglomerates company?
A good EBIT depends on the Conglomerates industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Aran Research & Development (1982). Aran Research & Development (1982)'s current EBIT is ₪33.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aran Research & Development (1982) stock overvalued right now?
Based on GuruFocus' analysis, Aran Research & Development (1982) (XTAE:ARAN) is currently considered Fairly Valued. The stock's GF Value™ is ₪37.11, compared to a current price of ₪39.78 — trading 7.2% above its estimated fair value. The current EBIT is ₪33.6 Mil. Aran Research & Development (1982)'s overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Aran Research & Development (1982) (XTAE:ARAN), the current EBIT is ₪33.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aran Research & Development (1982) (XTAE:ARAN) Overvalued in 2026?

Based on GuruFocus' analysis, Aran Research & Development (1982) stock appears to be overvalued. The current stock price of ₪39.78 is trading 7.2% above its estimated GF Value™ of ₪37.11. GuruFocus considers Aran Research & Development (1982) to be Fairly Valued.

Key valuation signals for XTAE:ARAN:

  • EBIT: ₪33.6 Mil
  • GF Value™: ₪37.11 vs. price of ₪39.78 (7.2% above fair value)
  • GF Score™: 78/100 with 2 warning signs

No single metric tells the full story. See the XTAE:ARAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aran Research & Development (1982) Business Description

Address 43 HaEshel Street, P.O.B 3067, Caesarea Business Park, Tel Aviv, ISR, 3088900
Aran Research & Development (1982) Ltd is a product design and development company. It also manufactures equipment for the plastics industry. It develops & supplies products including medical devices, water, defense & HLS, consumer & industrial and injection molds. It also has medical startups which focuses on Cardiovascular, Laparoscopy and Gastrointestinal endoscopy.
78GF Score

Get the complete analysis for XTAE:ARAN

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪39.78
Price
₪37.11
GF Value